<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00512772</url>
  </required_header>
  <id_info>
    <org_study_id>B32220072383</org_study_id>
    <nct_id>NCT00512772</nct_id>
  </id_info>
  <brief_title>Improved Use of Antibiotic Guidelines in Hospital Environment</brief_title>
  <official_title>Improved Use of Antibiotic Guidelines in in Hospital Environment: Research on an Implementation Model and the Role of the Hospital Pharmacist.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Katholieke Universiteit Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the use of antibiotic guidelines and thus
      antibiotics can be improved through a description of possible barriers leading to tailored
      interventions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">823</enrollment>
  <condition>Community-Acquired Pneumonia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to the hospital with a diagnosis of community-acquired pneumonia or
        community-acquired pyelonephritis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed community-acquired pneumonia (CAP)

          -  Diagnosed community-acquired pyelonephritis

        Exclusion Criteria:

          -  CAP: hospital-acquired pneumonia; patients transferred from other hospital; death
             within 24h, aspiration pneumonia, immunocompromised status, palliative status,
             admission due to social reasons

          -  Pyelonephritis: urinary tract with functional or physical abnormalities, urinary
             catheterisation, pregnancy, (immunocompromised status, palliative status, admission
             due to social reasons and history of renal transplant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pieter-Jan Cortoos, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Katholieke Universiteit Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gert Laekeman, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Katholieke Universiteit Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2007</study_first_submitted>
  <study_first_submitted_qc>August 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2007</study_first_posted>
  <last_update_submitted>December 17, 2010</last_update_submitted>
  <last_update_submitted_qc>December 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Pieter-Jan Cortoos, PharmD</name_title>
    <organization>Katholieke Universiteit Leuven</organization>
  </responsible_party>
  <keyword>Time series</keyword>
  <keyword>Implementation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

